astemizole has been researched along with mefloquine hydrochloride in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (61.54) | 29.6817 |
2010's | 4 (30.77) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
Keserü, GM | 1 |
Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, X; Chong, CR; Liu, JO; Shi, L; Sullivan, DJ | 1 |
Jia, L; Sun, H | 1 |
Adrián, F; Anderson, P; Brinker, A; Caldwell, JS; Chatterjee, A; Gray, NS; Henson, K; Janes, J; Kato, N; Kuhen, K; Matzen, JT; McNamara, C; Nagle, A; Nam, TG; Plouffe, D; Schultz, PG; Trager, R; Winzeler, EA; Yan, SF; Zhou, Y | 1 |
Biagini, GA; Chandramohanadas, R; Darling, C; DeGrado, WF; Diamond, SL; Fisher, N; Greenbaum, DC; Jing, H; Jo, H; Lucumi, E; Napper, AD; Shone, AE; Ward, SA | 1 |
Sen, S; Sinha, N | 1 |
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y | 1 |
Mowrey, DD; Sun, T; Tang, P; Tillman, TS; Wells, MM; Xu, Y | 1 |
Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
1 review(s) available for astemizole and mefloquine hydrochloride
Article | Year |
---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
12 other study(ies) available for astemizole and mefloquine hydrochloride
Article | Year |
---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A clinical drug library screen identifies astemizole as an antimalarial agent.
Topics: Animals; Antimalarials; Astemizole; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance; Drug Resistance, Multiple; Humans; Mice; Plasmodium falciparum; Plasmodium yoelii | 2006 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug Resistance; Folic Acid Antagonists; Malaria; Models, Molecular; Parasites; Plasmodium falciparum; Reproducibility of Results; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2008 |
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
Topics: Animals; Antimalarials; Drug Resistance, Multiple; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance; Erythrocytes; Humans; Imidazoles; Liver; Malaria; Mice; Mice, Inbred BALB C; Molecular Structure; Piperazines; Plasmodium; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Polymorphism, Single Nucleotide; Protozoan Proteins; Random Allocation; Small Molecule Libraries; Sporozoites | 2011 |
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
Topics: Analgesics, Non-Narcotic; Animals; Binding Sites; Cannabinoids; Drug Evaluation, Preclinical; Female; Lipids; Molecular Dynamics Simulation; Molecular Targeted Therapy; Nuclear Magnetic Resonance, Biomolecular; Oocytes; Pain; Protein Conformation; Protein Structure, Tertiary; Receptors, Glycine; Reproducibility of Results; Xenopus laevis | 2015 |